Skip to main content
. 2020 Aug 6;10:13. doi: 10.1186/s13569-020-00135-7

Fig. 6.

Fig. 6

One way sensitivity analysis evaluating incremental cost effectiveness ratios (ICERs) of CIUP compared with UAPR for a range of costs of imatinib. For all values of imatinib price, no meaningful ICER is accrued. In the setting of the known finding of CIUP having less effectiveness, this suggests that it is the more costly strategy overall regardless of imatinib cost